Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H33O6.K |
Molecular Weight | 456.6135 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[H][C@@]12CC[C@@](O)(CCC([O-])=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])[C@@H](CC4=CC(=O)CC[C@]34C)C(=O)OC
InChI
InChIKey=FYLPNLCXMZDAEE-CKPGHUGTSA-M
InChI=1S/C24H34O6.K/c1-22-8-4-15(25)12-14(22)13-16(21(28)30-3)20-17(22)5-9-23(2)18(20)6-10-24(23,29)11-7-19(26)27;/h12,16-18,20,29H,4-11,13H2,1-3H3,(H,26,27);/q;+1/p-1/t16-,17+,18+,20-,22+,23+,24-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/864608
Sources: https://www.ncbi.nlm.nih.gov/pubmed/864608
Mexrenoate potassium is an aldosterone antagonist, which was developed as an antihypertensive agent. However, this drug has never been marketed.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
41020-67-1
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
23667632
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
3727
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
Mexrenoate potassium
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
C175819
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
AZR13V2X75
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY | |||
|
SUB08934MIG
Created by
admin on Fri Dec 15 18:25:44 GMT 2023 , Edited by admin on Fri Dec 15 18:25:44 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD